Endothelin-1-induced vasoconstriction is inhibited during erection in rats

T. M. Mills, D. M. Pollock, Ronald W Lewis, H. S. Branam, C. J. Wingard

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Recent evidence indicates that endothelin-1 (ET-1) might be a principal vasoconstrictor in the penis. We report that ET-1 injection into the cavernous sinuses before erection sharply reduced the magnitude of subsequent erections. Corpus cavernosum pressure-to-mean arterial pressure ratios (CCP/MAP), with maximal ganglionic stimulation, were 0.62 ± 0.05 before ET-1 injection and 0.31 ± 0.05 after, indicating that ET-1 acted as a vasoconstrictor. When ET-1 was injected during a maximal neurally induced erection, the ability of ET-1 to attenuate subsequent erections was diminished (CCP/MAP 0.75 ± 0.02 before ET-1, 0.61 ± 0.03 after). At submaximal stimulation voltages, injection of ET-1 during erection also attenuated its vasoconstrictive effect. Similarly, when ET-1 was injected during erection induced by intracavernosal injection of the nitric oxide (NO) donor NOR-1, subsequent erections were not significantly suppressed (CCP/MAP 0.53 ± 0.04 before ET-1, 0.45 ± 0.04 after). These findings that ET-1-induced vasoconstriction is attenuated during erection are consistent with the hypothesis that NO mediates erection both by initiating pathways that cause smooth muscle relaxation and by inhibiting the vasoconstrictive actions of ET-1.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume281
Issue number2 50-2
StatePublished - Aug 29 2001

Fingerprint

Endothelin-1
Vasoconstriction
Arterial Pressure
Injections
Vasoconstrictor Agents
Pressure
Cavernous Sinus
Muscle Relaxation
Nitric Oxide Donors
Penis
Smooth Muscle
Nitric Oxide

Keywords

  • Nitric oxide donors
  • Nonadrenergic noncholinergic stimulation
  • Smooth muscle relaxation

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Endothelin-1-induced vasoconstriction is inhibited during erection in rats. / Mills, T. M.; Pollock, D. M.; Lewis, Ronald W; Branam, H. S.; Wingard, C. J.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 281, No. 2 50-2, 29.08.2001.

Research output: Contribution to journalArticle

Mills, T. M. ; Pollock, D. M. ; Lewis, Ronald W ; Branam, H. S. ; Wingard, C. J. / Endothelin-1-induced vasoconstriction is inhibited during erection in rats. In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 2001 ; Vol. 281, No. 2 50-2.
@article{c448f279dc1c4ff5b2b31ce36788ca0d,
title = "Endothelin-1-induced vasoconstriction is inhibited during erection in rats",
abstract = "Recent evidence indicates that endothelin-1 (ET-1) might be a principal vasoconstrictor in the penis. We report that ET-1 injection into the cavernous sinuses before erection sharply reduced the magnitude of subsequent erections. Corpus cavernosum pressure-to-mean arterial pressure ratios (CCP/MAP), with maximal ganglionic stimulation, were 0.62 ± 0.05 before ET-1 injection and 0.31 ± 0.05 after, indicating that ET-1 acted as a vasoconstrictor. When ET-1 was injected during a maximal neurally induced erection, the ability of ET-1 to attenuate subsequent erections was diminished (CCP/MAP 0.75 ± 0.02 before ET-1, 0.61 ± 0.03 after). At submaximal stimulation voltages, injection of ET-1 during erection also attenuated its vasoconstrictive effect. Similarly, when ET-1 was injected during erection induced by intracavernosal injection of the nitric oxide (NO) donor NOR-1, subsequent erections were not significantly suppressed (CCP/MAP 0.53 ± 0.04 before ET-1, 0.45 ± 0.04 after). These findings that ET-1-induced vasoconstriction is attenuated during erection are consistent with the hypothesis that NO mediates erection both by initiating pathways that cause smooth muscle relaxation and by inhibiting the vasoconstrictive actions of ET-1.",
keywords = "Nitric oxide donors, Nonadrenergic noncholinergic stimulation, Smooth muscle relaxation",
author = "Mills, {T. M.} and Pollock, {D. M.} and Lewis, {Ronald W} and Branam, {H. S.} and Wingard, {C. J.}",
year = "2001",
month = "8",
day = "29",
language = "English (US)",
volume = "281",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "2 50-2",

}

TY - JOUR

T1 - Endothelin-1-induced vasoconstriction is inhibited during erection in rats

AU - Mills, T. M.

AU - Pollock, D. M.

AU - Lewis, Ronald W

AU - Branam, H. S.

AU - Wingard, C. J.

PY - 2001/8/29

Y1 - 2001/8/29

N2 - Recent evidence indicates that endothelin-1 (ET-1) might be a principal vasoconstrictor in the penis. We report that ET-1 injection into the cavernous sinuses before erection sharply reduced the magnitude of subsequent erections. Corpus cavernosum pressure-to-mean arterial pressure ratios (CCP/MAP), with maximal ganglionic stimulation, were 0.62 ± 0.05 before ET-1 injection and 0.31 ± 0.05 after, indicating that ET-1 acted as a vasoconstrictor. When ET-1 was injected during a maximal neurally induced erection, the ability of ET-1 to attenuate subsequent erections was diminished (CCP/MAP 0.75 ± 0.02 before ET-1, 0.61 ± 0.03 after). At submaximal stimulation voltages, injection of ET-1 during erection also attenuated its vasoconstrictive effect. Similarly, when ET-1 was injected during erection induced by intracavernosal injection of the nitric oxide (NO) donor NOR-1, subsequent erections were not significantly suppressed (CCP/MAP 0.53 ± 0.04 before ET-1, 0.45 ± 0.04 after). These findings that ET-1-induced vasoconstriction is attenuated during erection are consistent with the hypothesis that NO mediates erection both by initiating pathways that cause smooth muscle relaxation and by inhibiting the vasoconstrictive actions of ET-1.

AB - Recent evidence indicates that endothelin-1 (ET-1) might be a principal vasoconstrictor in the penis. We report that ET-1 injection into the cavernous sinuses before erection sharply reduced the magnitude of subsequent erections. Corpus cavernosum pressure-to-mean arterial pressure ratios (CCP/MAP), with maximal ganglionic stimulation, were 0.62 ± 0.05 before ET-1 injection and 0.31 ± 0.05 after, indicating that ET-1 acted as a vasoconstrictor. When ET-1 was injected during a maximal neurally induced erection, the ability of ET-1 to attenuate subsequent erections was diminished (CCP/MAP 0.75 ± 0.02 before ET-1, 0.61 ± 0.03 after). At submaximal stimulation voltages, injection of ET-1 during erection also attenuated its vasoconstrictive effect. Similarly, when ET-1 was injected during erection induced by intracavernosal injection of the nitric oxide (NO) donor NOR-1, subsequent erections were not significantly suppressed (CCP/MAP 0.53 ± 0.04 before ET-1, 0.45 ± 0.04 after). These findings that ET-1-induced vasoconstriction is attenuated during erection are consistent with the hypothesis that NO mediates erection both by initiating pathways that cause smooth muscle relaxation and by inhibiting the vasoconstrictive actions of ET-1.

KW - Nitric oxide donors

KW - Nonadrenergic noncholinergic stimulation

KW - Smooth muscle relaxation

UR - http://www.scopus.com/inward/record.url?scp=0034886178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034886178&partnerID=8YFLogxK

M3 - Article

C2 - 11448850

AN - SCOPUS:0034886178

VL - 281

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 2 50-2

ER -